<DOC>
	<DOCNO>NCT02860598</DOCNO>
	<brief_summary>Anemia concern lot patient cancer affect quality life ( QOL ) . Numerous study oncology demonstrated benefit erythropoiesis-stimulating agent ( ESA ) treatment anemia . ESAs allow improvement QOL , hemoglobin level ( Hb ) validate alternative transfusion . However , hematology , specific recommendation use ESAs lymphoid pathology , none myeloid disorder context autografts allogeneic hematopoietic stem-cell transplantation ( HSCT ) . Thus , investigator particular interested indication : treatment anemia acute myeloid leukemia ( AML ) patient treat chemotherapy , patient receive myeloablative non-myeloablative conditioning allogeneic HSCT , whatever type donor cell source .</brief_summary>
	<brief_title>Observatory Prescription Erythropoietin Treatment Anemia Induced Chemotherapy Allograft Conditioning Among Patients With Haematological Malignancy</brief_title>
	<detailed_description>In context , prospective observatory conduct 2006 2009 hematology department Prof. Michallet assess impact prescribe ESAs ( epoetin beta darbepoetin ) two distinct patient population . A significant improvement QOL six-month follow- observed group . The effectiveness ESA red cell recovery reduction red blood cell transfusion establish compare evolution Hb transfusion need population ESA match population . Moreover , significant difference occurrence thromboembolic event survival progression-free survival observe ESA group control group .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age ≥ 18 year . Patient AML de novo secondary myelodysplasia Complete Remission ( CR ) induction / salvage therapy candidate receive consolidation therapy . OR Patient hematologic malignancy ( ALL , AML , chronic lymphocytic leukemia , CLL , nonHodgkin lymphoma , MDS , myeloma , myeloproliferative syndrome ) candidate blood marrow stem cell placental blood transplantation . Depending hematologic malignancy , pretransplant status patient include CR , good partial partial response . Patient anemia ( Hb blood level ≤ 110g / l ) induce consolidation chemotherapy allograft conditioning ( myeloablative nonmyeloablative ) . Patient eligible accord investigator , treatment ESA ( evaluation investigator benefice risk ratio ) . Written informed consent . Contraindication epoetin alfa epoetin zeta . Patient able receive adequate antithrombotic prophylaxis . Patients receive ESA therapy within 3 week prior inclusion . non Frenchspeaking patient Patient participate participate clinical trial evaluate novel molecule 30 day inclusion . pregnant nursing , woman woman childbearing potential without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ESAs</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>AML</keyword>
	<keyword>HSCT</keyword>
</DOC>